• H. Dunbar Hoskins Jr., MDThe H. Dunbar Hoskins Jr., M.D. Center for Quality Eye Care was established as a quality of care and health policy research center that advances the accessibility to and appropriateness of eye care services. The work of the Hoskins Center will help ensure that patients continue to receive high quality, evidence-based eye care within a tightening economic environment that demands increased value for services provided.

  • from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Intravitreal anti-VEGF and corticosteroid therapeutics are effective for the treatment of diabetic macular edema. Cataract progression and ocular hypertension are potential adverse events related to corticosteroid therapy. The literature does not conclusively assess comparat…
    Ophthalmic Technology Assessment
    from AAO PPP Panels, Hoskins Center for Quality Eye Care
    Recommendations distilled from the various Preferred Practice Pattern® (PPP) Guidelines titles.
    Summary Benchmark Translations
    from AAO PPP Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Recommendations distilled from the PPPs for AMD; diabetic retinopathy; idiopathic epiretinal membrane and vitreomacular traction; idiopathic macular hole; posterior vitreous detachment, retinal breaks, and lattice degeneration; retinal and ophthalmic artery occlusions; and r…
    Summary Benchmark Translations
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Diabetic Retinopathy.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Age-Related Macular Degeneration.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Retinal Vein Occlusions.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Idiopathic Macular Hole.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Idiopathic Epiretinal Membrane and Vitreomacular Traction.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Retinal and Ophthalmic Artery Occlusions.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration.
    Preferred Practice Pattern Guideline
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and effective for neovascular AMD over 2 years. Further research is needed to evaluate long-term safety and comparative efficacy of these agents.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Strong evidence indicates intravitreal pharmacotherapy with anti-VEGF agents is a safe and effective therapy for ME secondary to BRVO. Intravitreal corticosteroids are associated with greater side effects and VA is less optimal with laser photocoagulation treatments.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence suggests that combination intravitreal foscarnet and systemic therapy may be more effective than systemic therapy in the treatment of acute retinal necrosis (ARN). While PCR testing reliably confirms ARN cases, antiviral treatment must not be delayed.
    Ophthalmic Technology Assessment
    from AAO Quality of Care Secretariat, Hoskins Center for Quality Eye Care
    Provides consensus recommendations for screening low risk and high risk patients for chloroquine and hydroxychloroquine toxicity. Published in Ophthalmology, March 2016, Vol. 123, 1386-1394.
    Clinical Statement
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review on the effectiveness of routine nonsteroidal anti-inflammatory drug (NSAID) treatment to prevent vision loss from cystoid macular edema at ≥3 months after cataract surgery
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review pertaining to the efficacy and safety of therapies for the treatment of macular edema associated with central retinal vein occlusion (CRVO)
    Ophthalmic Technology Assessment
    from AAO Task Force on Genetic Testing
    The Academy's Task Force report on genetic testing that provides guidance on the underlying principles and approaches of genetic testing.
    Clinical Statement
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review of the literature for the outcomes and safety of interventions for toxoplasma retinochoroiditis
    Ophthalmic Technology Assessment
    from AAP, AAPOS and AAO Hoskins Center for Quality Eye Care
    The American Academy of Pediatrics (AAP), American Association for Pediatric Ophthalmology and Strabismus (AAPOS), and Academy outline principles of a screening program to detect ROP in infants at risk; includes suggested guidelines for the United States.
    Clinical Statement
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review of the literature supporting the treatment of diabetic macular edema with anti-VEGF pharmacotherapy
    Ophthalmic Technology Assessment